(Q24244836)

7

George A Wells

0 references

Tanveer Towheed

5

Tanveer Towheed

0 references

Sarah Rose C Garner

1

Sarah E Garner

0 references

Ruth Frankish

3

Ruth R Frankish

0 references

author name string

Dogan Fidan

2

0 references

Maria Judd

Cochrane Database of Systematic Reviews

4

0 references

publication date

24 January 2005

0 references

published in

0 references

cites work

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Renal effects of COX-2-selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

ACR 20: clinical or statistical significance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003685.PUB2